Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-07-01-Speech-2-156"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-07-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Strengthening the European pharmaceutical industry in the interest of patients – proposals for action2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20030701.6.2-156"2
lpv:hasSubsequent	lp_eu:2003-07-01-Speech-2-1572
lpv:speaker	lp:Liikanen2
lpv:spoken text	". Mr President, as far as the developing countries are concerned, there are three main possibilities in terms of action: firstly, to create a legislative framework that encourages research on orphan drugs to treat what are on our territories rare diseases. There, we have a directive that was adopted by Parliament some time ago, and that framework is in place. Secondly, the question is that if that is not enough to provide an incentive for research work, the question of public research funding can be raised. I am sorry that Mr Busquin, the Commissioner for Research, is not here. I am sure he would be in a position to provide a more detailed reply to that. Thirdly, there are the issues of the needs of developing countries, which are based on the low level of income and lower purchasing power of the citizens. In that area, there has been some progress in recent years. The issue is still being discussed in the WTO context on the one hand. On the other, there have been schemes which have allowed developing countries to purchase certain medicines at a lower price than in Europe. Things are moving, but I am sure that the situation today is far from satisfactory."@en1
lpv:unclassifiedMetadata	"Commission"1 "Liikanen,"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph